MedTrace Logo

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines

NCT03241303 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-03-26

No results posted yet for this study

Summary

Investigation of GLP-1 signalling in the glucose-lowering effect of increased carbohydrate content in the distal small intestines induced by alpha-glucosidase inhibition during meal ingestion in patients with type 2 diabetes

Conditions

  • Glucose Metabolism Disorders

Interventions

DRUG

Acarbose

Glucobay tablets on experimental day.

DRUG

Placebo Oral Tablet

Placebo tablets on experimental day.

DRUG

Exendin (9-39)

Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.

DRUG

Placebo Saline

9 mg/ml placebo saline infusion on experimental day.

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, PhD · University Hospital, Gentofte, Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2018-01-01
Completion
2018-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03241303 on ClinicalTrials.gov